Patient education program at the forefront of cancer-associated thrombosis care

Sebuhyan, Maxime; Crichi, Benjamin; Deville, Laure; Maignan, Christine Le; Marjanovic, Zora; Rueda, Juan David; Bensaoula, Okba; Ndour, Arlette; Frère, Corinne; Madeleine, Isabelle; Farge, Dominique

doi:10.1016/j.jdmv.2021.08.001

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients should be instructed about relevant bleeding symptoms and how to manage them at any time. 220 For each of these scenarios, a potential bleeding history was discussed, varying in severity from asymptomatic to mild mucocutaneous bleeding to severe gastrointestinal bleeding.…”

Section: Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

Parmentier,

Koschmieder,

Henze

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

Active cancer by itself but also chemotherapy is associated with an increased risk of cardiovascular disease (CVD) and especially coronary artery disease (CAD) and atrial fibrillation (AF). The frequency of CVD, CAD, and AF varies depending on comorbidities (particularly in older patients), cancer type, and stage, as well as the anticancer therapeutic being taken. Many reports exist for anticancer drugs being associated with CVD, CAD, and AF, but robust data are often lacking. Because of this, each patient needs an individual structured approach concerning thromboembolic and bleeding risk, drug–drug interactions, as well as patient preferences to evaluate the need for anticoagulation therapy and targeting optimal symptom control. Interruption of specific cancer therapy should be avoided to reduce the potential risk of cancer progression. Nevertheless, additional factors like thrombocytopenia and anticoagulation in the elderly and frail patient with cancer cause additional challenges which need to be addressed in daily clinical management. Therefore, the aim of these recommendations is to summarize the available scientific data on antithrombotic therapy (both antiplatelet and anticoagulant therapy) in cancer patients with CVD and in cases of missing data providing guidance for optimal careful decision-making in daily routine.

show abstract

Section: Recommendationsmentioning

confidence: 99%

“…Patients should be instructed about relevant bleeding symptoms and how to manage them at any time. 220 Simple and comprehensive treatment plans should support patient empowerment…”

Section: Antithrombotic Agents and Cancer-directed Therapymentioning

confidence: 99%

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

Parmentier,

Koschmieder,

Henze

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

show abstract

“…Awareness improves adherence to the proposed treatments. Therefore, a patient education program dedicated to CAT is feasible and desirable to improve cancer patient empowerment, compliance with CAT treatment and quality of life [ 82 ]. Adherence to treatment and the quality of life of patients with cancer and VTE are impaired, especially if patients are treated with LMWHs.…”

Section: Pathophysiology Of Vte In Cancer Patientsmentioning

confidence: 99%

Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients’ and Clinicians’ Awareness

Zalunardo

Panzavolta

Bigolin

et al. 2022

Life

View full text Add to dashboard Cite

Cancer is a leading cause of death. Venous thromboembolism (VTE) is an often-overlooked cause of morbidity and mortality in cancer patients that can be readily prevented and treated. Actions are needed to reduce the morbidity and mortality of patients with cancer-associated thrombosis (CAT). There is a need to increase awareness of the impact of CAT on cancer patients’ morbidity and mortality, on their quality of life and to understand the importance of more effective preventions and treatments of VTE in cancer patients. Moreover, it is of great importance to systematically assess the risk of VTE in regard to patients, cancer and treatment-related factors. Unfortunately, there are unmet clinical needs in the prevention and treatment of cancer-associated VTE. In this review, we discuss an action plan to ensure an increased awareness of and education on the issues that need to be addressed in order to improve the provision of appropriate prevention, early diagnosis and effective and safe treatment of VTE to all cancer patients and, ultimately, to reduce morbidity and mortality.

show abstract

Measurement of adherence and health-related quality of life during anticoagulation therapy in cancer-associated venous thromboembolism (VTE): a multicenter quantitative study

Font,

Gomez-Mesa,

López-Núñez

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

Therapy for cancer associated-venous thromboembolism (VTE) includes long term anticoagulation, which may have substantial impact on the health-related quality of life (HRQL) of patients. We assessed patient-reported outcomes to characterize the HRQL associated with VTE treatment and to begin to examine those HRQL elements impacting anticoagulation adherence (AA). MethodsParticipants were adult cancer patients with con rmed symptomatic acute lower extremity deep venous thrombosis. Patients were excluded if there was an indication for anticoagulation other than VTE, ECOG performance status > 3 or life expectancy < 3 months. Participants were assessed with a self-reported adherence tool. HRQL was measured with a 6-domain questionnaire using a seven-point Likert scale.Evaluations were performed at 30 days and 3 months after enrollment. For the primary objective, an overall adherence rate was calculated at each time point of evaluation. For the HRQL domains, nonparametric testing was used to compare results between subgroups. Results74 patients were enrolled. AA and HRQL at 30 days and 3 months were assessed in 50 and 36 participants, respectively. At 30 days the AA rate was 90% and at 3 months it was 83%. In regard to HRQL, patients suffered frequent and moderate-severe distress in the domains of emotional and physical symptoms, sleep disturbance and limitations to physical activity. An association between emotional or physical distress and AA was observed. ConclusionPatients with VTE suffer a substantial impairment of their HRQL. Increased distress correlated with better AA. These results can be used to inform additional research aimed at developing novel strategies to improve AA. BackgroundUp to 15% of all cancer patients develop venous thromboembolism (VTE) every year, and cancerassociated VTE causes signi cant morbidity and mortality [12,34]. The current standard of care for treatment of cancer associated-VTE is anticoagulation using low molecular weight heparin (LMWH) and/or direct oral anticoagulants (DOAC) for as long as cancer is active or the patient is receiving antineoplastic therapy [6,15,17, 18]. There are accumulating data, using both general and VTE-speci c

show abstract

Patient education program at the forefront of cancer-associated thrombosis care

Cited by 3 publications

References 26 publications

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients’ and Clinicians’ Awareness

Measurement of adherence and health-related quality of life during anticoagulation therapy in cancer-associated venous thromboembolism (VTE): a multicenter quantitative study

Contact Info

Product

Resources

About